×

Food and Staples Retailing Drug Retail

  • Nov 16- Canadian grocery and pharmacy retailer Loblaw Cos Ltd reported a 25.5 percent rise in quarterly profit, helped by a drop in expenses and improved performances by its financial services and property businesses. Adjusted net earnings attributable to shareholders rose to C $512 million, or C $1.26 per share, in the third quarter ended Oct. 8, from C $408...

  • Drug pricing pressure

    CNBC's Meg Tirrell speaks with Alkermes Chairman & CEO Richard Pops at the Partnering for Cures conference about drug pricing, his company's new depression drug and the opioid epidemic.

  • A study comparing three popular arthritis drugs shows they're all about equally safe and equally dangerous for the heart, reports NBC.

  • Nov 8- CVS Health Corp, the No. 2 U.S. drugstore chain by store count, reported a 15.5 percent rise in quarterly revenue, helped by strong demand for its pharmacy benefit management services. Net income attributable to CVS rose to $1.54 billion, or $1.43 per share, in the third quarter ended Sept. 30, from $1.25 billion, or $1.11 per share, a year earlier.

  • Cali's drug price brawl

    CNBC's Meg Tirrell reports the latest surrounding California's Proposition 61.

  • New war on drugs: Pharma becoming 'uninvestable'?

    Bill George, Harvard Business School Professor and former Medtronic Chairman and CEO, and David Maris, Wells Fargo Securities Specialty Pharmaceutical Analyst, weigh in on the ongoing drug-pricing war.

  • Big pharma's big problem

    CNBC's Meg Tirrell discusses the timeline on the war on drug pricing.

  • Nov 3- CVS Health Corp said it would cut about 600 jobs, mostly at its corporate offices in Rhode Island, Illinois and Arizona over the next two months, citing an increasingly competitive environment. The drugstore chain operator, which is expected to report third-quarter results next week, employs more than 240,000 people in the United States.

  • Generic drug probe charges to be filed by year end -Rpt

    CNBC's Dominic Chu reports on possible charges being filed by the Justice Department against some generic drugmakers, according to Bloomberg.

  • Gilead Q3 EPS misses, revenues beat

    Earnings are out for Gilead. CNBC's Meg Tirrell reports the details. “Fast Money” trader Jon Najarian weighs in.

  • Drug Price Relief Act battle

    Debating whether California voters should pass Proposition 61, the Drug Price Relief Act, with Scott Gottlieb, physician and American Enterprise Institute Resident Fellow, and Zeke Emanuel, University of Pennsylvania vice provost for global initiatives.

  • Cramer: The drug wholesale price war has officially begun — steer clear

    Jim Cramer addressed the stunning decline in McKesson, and got to the bottom of what triggered the sudden fall in the stock.

  • Washington's next biotech target?

    CNBC's Meg Tirrell reports the latest surrounding Ariad Pharmaceuticals and the company's drug price hike.

  • Ariad cancer drug pricing under congressional scrutiny

    CNBC's Meg Tirrell reports the latest on a tweet sent by Sen. Bernie Sanders about Ariad Pharmaceuticals' cancer drug pricing.

  • A Walgreens store in Boston.

    Walgreens Boots Alliance reported a jump in quarterly profit and said it now expected its acquisition of Rite Aid Corp to close in early 2017.

  • Kaine: Can't imagine savvy financial person prefers Trump

    Democratic vice presidential candidate Tim Kaine discusses Donald Trump's tax plan and Hillary Clinton's Catholic comments in the Wikileaks emails.

  • Kaine: Estate tax is something we should maintain

    Democratic vice presidential candidate Tim Kaine discusses lowering drug prices, Wall Street and regulation and estate taxes.

  • California's drug pricing bill

    CNBC's Meg Tirrell reports the latest on the controversy surrounding the California Drug Price Relief Act including the Bernie Sanders' support for the proposition.

  • Copay assistance: Doing more harm than good?

    Dr. Peter Bach, Memorial Sloan Kettering physician, discusses how copay assistance programs are actually causing drug prices to rise.

  • Copay assistance could raise drug costs

    CNBC's Meg Tirrell discusses implications surrounding co-pay assistance programs.